Novel Treatment Advances and Approaches in Rheumatoid Arthritis: Personalizing Therapy
for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 10, 2018 to August 10, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

Description:
RA is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. According to the ACR, it is estimated that over 1.3 million people suffer from RA in the United States. Treatment regimens vary and carry important differences between therapeutic options that are clinically relevant to healthcare providers. Only about 1/3 of patients treated for RA ever achieve clinical remission. The remaining patients can experience continuous disease progression and disability. In addition, many patients will have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Fortunately, new and emerging treatment strategies may offer additional therapeutic options to address the unmet needs of these patients. Clinicians have recently been equipped with more treatment options, including IL-6 receptor antagonists. These new options have shown improved efficacy and safety in RA, and healthcare professionals must be educated on these agents and the potential risks that come along with any treatment option. This presentation on integrating emerging therapies into the treatment paradigm will address this gap in knowledge by providing attendees with updated treatment strategies, tools, guidelines, and successful evidence-based treatment approaches from recent clinical trial data.

Upon completion of this activity, participants will be able to:

  • Analyze the efficacy and safety data of current and emerging biologic therapies, including IL-6 inhibitors, for the treatment of moderate-to-severe rheumatoid arthritis (RA) for achieving individualized treatment goals

  • Examine the proinflammatory cellular and cytokine networks underlying localized and systemic RA pathophysiology

  • Tailor treatment regimens for moderate-to-severe RA based on ongoing monitoring of disease activity, functional status, treatment response, and other patient-specific factors

  • Interpret results of decision support tools with health plan affiliated rheumatology professionals to improve outcomes for patients with RA

  • Explore strategies to monitor and manage adverse events associated with newer therapies in RA management in order to improve patient adherence
     

Faculty: Jeffrey Curtis, MD, MS, MPH
Marguerite Jones Harbert – Gene Ball Endowed Professor of Medicine
UAB Division of Clinical Immunology & Rheumatology

Disclosure:

Dr. Curtis has no relevant financial relationships to disclose. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue